104 results about "Renal Failures" patented technology

The compositions comprise at least two ingredients selected from the group consisting of fish oil, L-arginine, vitamin E, vitamin C, vitamin B3, vitamin B5, vitamin B6, vitamin B1, vitamin B2, folic acid, biotin, vitamin B12, and are formulated for the prevention and / or treatment of a disease or condition associated with muscle decline in a subject in need thereof. Preferably, the subject in need is an individual at risk of or having renal failure, renal dysfunction or / and nephropathy, such as chronic nephropathy, protein energy consumption, end-stage nephropathy, renal failure due to hospitalization in an intensive care unit, acute kidney injury, and the muscle decline is selected from the group consisting of muscle depletion, muscle loss due to renal failure or dysfunction, muscle decline associated with chronic kidney disease, muscle loss due to hospitalization in intensive care units during renal failure, metabolic acidosis during chronic kidney disease, protein energy depletion, or a combination thereof. The method enables the prevention and / or treatment of at least one outcome of a disease or condition associated with muscle decline in a subject at risk of or having renal failure, renal dysfunction or / and kidney disease. The composition and the method can be used to improve the level of at least one amino acid.

The invention provides application of enhanced mesenchymal stem cells and exosomes in chronic nephritis and renal failure, and belongs to the technical field of biological medicine manufacturing. Through composite pretreatment of salidroside and astragalus polysaccharide, the treatment potential of exosomes secreted by the mesenchymal stem cells is remarkably enhanced, a new thought is provided for intervention of the chronic kidney diseases, and various pathologies of the chronic kidney diseases are covered. In addition, a 3D microenvironment constructed by fibrin gel is combined to simulate an in-vivo extracellular matrix, the natural growth state of the stem cells is better fitted, directional differentiation and function regulation of the stem cells are promoted, and therefore the biological activity and targeting performance of the exosome are improved.

The invention belongs to the technical field of biological medicines, and particularly relates to application of a BACE2 inhibitor and a composition in preparation of a medicine for treating arteriovenous fistula stenosis after renal failure. The invention provides an application of a BACE2 inhibitor and a composition thereof in preparation of drugs for prevention, adjuvant therapy or treatment of arteriovenous fistula stenosis after renal failure. According to the medicine, by reducing the expression level of BACE2 and reducing the content of soluble sVEGFR3, construction of a lymphatic network on the surface of arteriovenous fistula after renal failure is promoted, inflammation infiltration is relieved or neointima production is relieved, and the effects of prevention, adjuvant therapy or treatment of arteriovenous fistula stenosis after renal failure are achieved. The BACE2 inhibitor composition provided by the invention is simple in preparation method, can play a role in slow release of the BACE2 inhibitor, and is an effective intervention means for preventing and treating arteriovenous fistula stenosis after renal failure.

The invention provides a non-classical ferroptosis inhibitor as well as a preparation method and application thereof, and belongs to the technical field of chemical synthesis medicines. The invention synthesizes a compound with a good inhibition effect on ferroptosis, the compound can be used for preparing a ferroptosis inhibitor, and the structure of the compound is shown as a formula I in the specification. The compound can be used for preparing medicines for preventing and / or treating ferroptosis-related neurodegenerative diseases, tissue ischemia-reperfusion injury, cerebral apoplexy, cardiovascular diseases, renal failure, inflammation, cardiotoxicity, acute organ injury, chronic atrophic gastritis or diabetic complications and other diseases, and has a wide market prospect. # imgabs0 #

The utility model provides a bioreactor device for replacing the function of a renal tubule, the bioreactor device is placed in a cell culture incubator, the bioreactor device comprises a fixed frame and a chip, the chip is arranged on the fixed frame, and a vein-imitated renal tubule structure is formed in the chip; openings in the two ends of the flow channel are respectively a liquid inlet and a liquid outlet; the inner diameter of the main flow channel is larger than that of the micro flow channel; wherein the inner diameter of the main flow channel and the inner diameter of the micro flow channel of the chip are both within the pipe diameter range of the physiological renal tubule; a human renal tubular epithelial cell suspension enters the vein-imitating flow channel from the liquid inlet and is attached to the inner wall of the vein-imitating flow channel. Therefore, the structure of the renal tubule is reflected in a more bionic and more reasonable manner, the physiological environment of the renal tubule can be simulated more accurately, a new design thought and method are provided for a renal tubule bioreactor device in a bioartificial kidney, the difficulty in the field of kidney replacement therapy is expected to be solved, and the life quality of patients with end-stage renal failure due to nephropathy is improved.

Provided herein are novel 2,4-dinitrophenol (DNP) derivatives and prodrugs of formula (I), as modulators of mitochondria functions, as well as pharmaceutical compositions comprising a compound described above and methods thereof for treating various diseases and disorders associated with or related to mitochondrial dysfunctions (e.g., obesity, diabetes, insulin resistance, liver diseases, heart or renal failure, neurodegenerative diseases or aging related diseases).

To provide a composition for preventing, ameliorating or treating a disease caused by protein nitration comprising a peptide with terminal tyrosine as an effective component.SOLUTION: A peptide with terminal tyrosine has an excellent effect of inhibiting protein nitration and also an excellent effect of preventing, ameliorating or treating disease symptoms in chronic immobilization stress-induced depression / cognitive impairment model, Alzheimer's disease model, epileptic seizure model, stroke model, type 2 diabetes model, acute renal failure model, or hyperammonemia model.SELECTED DRAWING: None

The present invention discloses phenyl-substituted dihydronaphthyridine compounds a preparation therefor and a use thereof, and belongs to the technical field of medicine. The compounds disclosed in the present invention are represented by formula I, and can be used as a mineralocorticoid receptor antagonist for treating, preventing or alleviating aldosteronism hyperplasia, diabetic nephropathy, hypertension, heart failure (comprising chronic heart failure, etc.), sequelae of myocardial infarction, liver cirrhosis, renal failure, stroke and other diseases in patients.

A renal failure therapy system includes a dialyzer; a blood circuit in fluid communication with the dialyzer; a dialysis fluid circuit in fluid communication with the dialyzer; a housing supporting the dialyzer, the blood circuit and the dialysis fluid circuit; and at least one electrical socket held by the housing, the electrical socket providing a voltage output dedicated to a particular voltage type of external electrical device for powering or charging the external electrical device, the at least one electrical socket including electrical insulation for protecting a patient while powering the external electrical device.

This invention belongs to the field of pharmaceutical analysis, specifically relating to a method for constructing a fingerprint spectrum of Shenfushu granules. The method for constructing a fingerprint spectrum of Shenfushu granules provided by this invention features high accuracy, high stability, good repeatability, good specificity, and strong specificity. The fingerprint spectrum analysis method for Shenfushu granules, a traditional Chinese medicine preparation for treating chronic renal failure, established by this invention can not only qualitatively analyze and identify the seven chemical components contained in this preparation, but also simultaneously present the characteristic peaks of five traditional Chinese medicines in the prescription, achieving the goal of overall quality control of multiple medicinal ingredients.

The present disclosure relates to a composition for use in preventing and / or treating renal failure, such as uremia, in a subject. Said composition is a composition for oral consumption and comprises i) an extract of Rhodiola rosea root, ii) L-arginine, iii) L-citrulline; and iv) an extract of beet root. Said composition is also useful for preventing or reducing a gain of body weight, or for reducing body weight, in a subject in need thereof.

The invention belongs to the technical field of biological medicines, and particularly relates to a traditional Chinese medicine composition for treating chronic renal failure of pets and a liposome and application thereof. According to the traditional Chinese medicine composition provided by the invention, by virtue of turmeric, eucommia ulmoides, medlar, astragalus membranaceus, poria cocos and beta-sitosterol, the aim of synergistically treating the renal failure in the aspects of resisting inflammation, inhibiting renal fibrosis, improving a glomerular filtration function, promoting kidney cell repair and the like can be achieved, and a new solution is provided for effectively treating the chronic renal failure of pets. The traditional Chinese medicine composition disclosed by the invention has a good recovery effect on kidney tissues of pets with chronic renal failure, can effectively reduce urea nitrogen and creatinine levels of blood of the pets with chronic renal failure, relieves renal failure symptoms, and has a good treatment effect; the liposome disclosed by the invention has the advantages of high effective rate, high cure rate and quick effect, and the treatment effect of the liposome is superior to that of a third-stage clinical medicine, namely beraprost, for treating the kidney renal failure of pets in the current market.

The application discloses a Bifidobacterium longum subsp.longum strain for relieving pathological characteristics of mice with chronic kidney disease induced by adenine, and belongs to the technical fields of microorganisms and medicines.The application provides a biomarker combination related to end-stage renal disease of peritoneal dialysis, wherein the corresponding species abundance in the biomarker combination presents significant difference in matched healthy control population and peritoneal dialysis population, can effectively distinguish the end-stage renal disease population of peritoneal dialysis and the healthy population, and has high sensitivity and specificity.The application also provides a Bifidobacterium longum subsp.longum strain CCFM1375 capable of delaying the progression of renal failure, which can be used for preparing products for improving chronic kidney disease.

The pharmaceutical composition for treating or preventing a fibrotic disease of the present invention contains a nucleic acid that inhibits the expression of mRNA encoding P4HA3. The fibrotic disease may be at least one disease selected from the group consisting of fibrosis, liver cirrhosis, renal failure, myocardial infarction, and cancer. The present invention provides a method for preventing or treating a fibrotic disease, which includes administering an effective amount of the pharmaceutical composition of the present invention to a subject suffering from or at risk of suffering from a fibrotic disease.

The present invention relates to an artificial intelligence model and an implementation method therefor, which are capable of selecting and extracting, from CT images of patients with IgA nephropathy, image features significant for prognostic prediction and applying same to a machine learning model to thereby predict, with high accuracy, the likelihood of the patients with IgA nephropathy progressing to end-stage renal failure within five years. The present invention provides a prognostic prediction model that rapidly predicts the prognosis of a patient without an invasive kidney biopsy, overcomes the limitations of conventional pathology diagnosis relying on invasive methods, and enables periodic prognostic evaluation with significantly improved reliability. In addition, the present invention is capable of precisely reflecting characteristics of each item and accurately predicting a clinical course of a patient, by combining various feature selection methods and binary classifiers for each item of mesangial hypercellularity (M), endothelial hypercellularity (E), segmental glomerulosclerosis (S), and tubular atrophy / interstitial fibrosis (T), which constitute a MEST score.

A medical device system includes renal failure therapy machines each including a memory. The renal failure therapy machines are communicatively coupled such that the memories collectively form a distributed database. The system also includes a logic implementer associated with each renal failure therapy machine. Each logic implementer is programmed to automatically access the distributed database, so that each renal failure therapy machine periodically delivers prescription input parameters and / or treatment output data to at least one of the other renal failure therapy machines, and retrieves prescription input parameters and / or treatment output data from at least one of the other renal failure therapy machines. One of the renal failure therapy machines is configured to create at least one treatment record trend from the treatment output data and to share the at least one treatment record trend with other renal failure therapy machines through the distributed database.

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using as says that detect Chitinase-3-like protein 1 as diagnostic and prognostic biomarker assays in renal injuries.

An extracorporeal and drug delivery system includes (i) a renal failure therapy machine operable with a blood filter in fluid communication with an arterial line and a venous line, the machine including (a) an effluent pump for pumping effluent from the blood filter at an effluent flowrate, and at least one of (b) a dialysis fluid pump for pumping dialysis fluid to the blood filter at a dialysis fluid flowrate, (c) a predilution pump for pumping replacement fluid into the arterial line at a predilution flowrate, or (d) a postdilution pump for pumping replacement fluid into the venous line at a postdilution flowrate; (ii) an infusion pump operable to deliver an intravenous (“IV”) drug to the patient at an IV drug flowrate; and (iii) a coordinating logic implementor configured to adjust the IV drug flowrate based on an amount of the IV drug removed via the effluent flowrate.

A renal failure therapy system includes a fresh dialysis fluid tube having a connector for connecting to a dialyzer, a spent dialysis fluid tube having a connector for connecting to the dialyzer, a dialysis fluid circuit including a fresh dialysis fluid line, a spent dialysis fluid line, at least one of (i) a first disinfection device positioned between the fresh dialysis fluid line and the fresh dialysis fluid tube, or (ii) a second disinfection device positioned between the spent dialysis fluid line and the spent dialysis fluid tube, and recirculation circuitry extending to a first machine connector for mating with the connector of the fresh dialysis fluid tube during disinfection and a second machine connector for mating with the connector of the spent dialysis fluid tube during disinfection. The system also includes a control unit configured to cause the first and second disinfection devices to be energized during the local disinfection.

The renal failure treatment system (10) includes: a fresh dialysis fluid (which may be flexible) tube (72) having a connector (72a) for connection to a dialyzer (102); a used dialysis fluid (which may be flexible) tube (74) having a connector (74a) for connection to the dialyzer (102); a dialysis fluid circuit (30) including: a fresh dialysis fluid line (70), a used dialysis fluid line (56), at least one of (i) a first disinfection device (90a) positioned between the fresh dialysis fluid line (70) and the fresh dialysis fluid tube (72) or (ii) a second disinfection device (90c) positioned between the used dialysis fluid line (70) and the used dialysis fluid tube (74), and a recirculation circuit that extends to (i) a first machine connector (28a) for mating with the connector (72a) of the fresh dialysis fluid tube (72) during local disinfection and (ii) a second machine connector (28c) for mating with the connector (74a) of the used dialysis fluid tube (74) during local disinfection; and a control unit (20) configured to energize the first or second disinfection device (90a, 90b) during local disinfection.

To provide a favorable combined extracorporeal and drug delivery system and method.SOLUTION: An extracorporeal and drug delivery system includes: (i) a renal failure therapy machine operable with a blood filter in fluid communication with an arterial line and a venous line, the machine including (a) an effluent pump for pumping an effluent from the blood filter at an effluent flowrate, and at least one of (b) a dialysis fluid pump for pumping a dialysis fluid to the blood filter at a dialysis fluid flowrate, (c) a predilution pump for pumping a replacement fluid into the arterial line at a predilution flowrate, and (d) a postdilution pump for pumping the replacement fluid into the venous line at a postdilution flowrate; (ii) an infusion pump operable to deliver an intravenous ("IV") drug to the patient at an IV drug flowrate; and (iii) a coordinating logic implementor configured to adjust the IV drug flowrate based on an amount of the IV drug removed via the effluent flowrate.SELECTED DRAWING: Figure 1

The invention provides a peritoneal dialysis device for renal failure, and belongs to the technical field of peritoneal dialysis. Comprising a positioning disc, an in-vivo dialysis tube, an in-vitro dialysis tube and a buffering assembly, the in-vivo dialysis tube and the in-vitro dialysis tube are installed on the positioning disc, the buffering assembly is used for buffering traction force on the in-vitro dialysis tube, the buffering assembly is further used for supporting and positioning the in-vivo dialysis tube, and the buffering assembly is connected with the positioning disc and a positioning plate. By arranging the buffer assembly, the in-vivo dialysis tube can be plastically fixed, the phenomenon that the in-vivo dialysis tube deviates and floats upwards after being used in the body of a patient for a long time is prevented, the difficulty of peritoneal dialysis operation of the patient is reduced, redundant in-vitro dialysis tubes outside the body of the patient can be stored, and the in-vivo dialysis tube fixing device is convenient to use. When the extracorporeal dialysis tube is pulled, the buffering assembly can absorb and buffer the pulling force at the first time, the situation that the pulling force directly acts on the skin of a patient, and consequently the patient feels uncomfortable is avoided, and the safety of the peritoneal dialysis device in daily use is improved.

A platform for patient engagement and treatment compliance is disclosed. In an example, a system includes a home therapy machine configured to perform a renal failure therapy treatment. The system also includes a mobile communication device including an application that enables a patient to select a program type for a future renal failure therapy treatment. The application is configured to determine a short program and a long program are available for the future renal failure therapy treatment and cause a user interface to provide an option to select one of the short program or the long program. The application is also configured to receive a selection of the short program or the long program via the user interface and transmit a message to the home therapy machine, the message indicative of the selection of the short program or the long program for the future renal failure therapy treatment.

The invention belongs to the technical field of biological medicines, and particularly discloses a liposome containing a natural extract composition as well as a preparation method and application of the liposome. The method for preparing the liposome containing the natural extract composition comprises the following steps: S1, adding the grape, poria cocos and apple extract, cholesterol and lecithin into an organic solvent, heating, stirring and dissolving to obtain an organic phase; adding the soybean extract and the ginseng extract into ultrapure water, heating and stirring to obtain a water phase; and S2, slowly adding the organic phase into the water phase while stirring, continuing stirring and emulsifying, and removing the organic solvent by reduced pressure distillation to obtain a liposome suspension. And S3, filtering the suspension, adding a freeze-drying protective additive, and freeze-drying to obtain the liposome. The invention also covers the application of the liposome in treating renal failure. In the invention, through the combination of natural extracts and the combination of a specific composition and liposome administration, the components generate a synergistic effect, and the pharmaceutical composition has a remarkable treatment effect on renal failure, especially chronic renal failure.

Methods, systems, and apparatuses for integrating medical device data are disclosed. In an example embodiment, an integration engine receives infusion therapy progress data from an infusion pump related to a patient identifier and receives renal failure therapy progress data from a renal failure therapy machine related to the same patient identifier. The integration engine determines fluid balance data based on a difference between at least some of the infusion therapy progress data and at least some of the renal failure therapy progress data and causes a combination user interface to display a trend of the fluid balance data within a fluid balance timeline. The integration engine determines when the trend of the fluid balance data exceeds a fluid balance limit and causes a fluid balance alarm or alert to be provided.

An object of the present invention is to improve the treatment and / or prevention of cardiovascular and renal diseases compared to already known monotherapies. A further object of the present invention is to provide a combination of pharmaceutical active ingredients for treating cardiovascular diseases, particularly cardiac and renal failure, characterized by chronic sodium retention, which reduces patient mortality and / or morbidity. Another object of the present invention is to improve the treatment and / or prevention of cardiovascular and renal diseases by administering a combination comprising finerenone and an SGLT2 inhibitor. [Solution] The present invention relates to pharmaceutical compositions and combinations comprising finerenone or its hydrate, solvate, or pharmaceutically acceptable salt or polymorph thereof, and an SGLT2 inhibitor or its hydrate, solvate, or pharmaceutically acceptable salt or polymorph thereof. The combinations can be used for the treatment and / or prevention of cardiovascular and / or renal diseases in humans and other mammals.

The invention discloses a 10H-phenoxazine compound as well as a preparation method and application thereof. The 10H-phenoxazine compound has a structure as shown in a formula (I). The invention also discloses application of the compounds and pharmaceutically acceptable salts thereof, or crystal forms thereof, or solvates thereof, or stereoisomers thereof in preparation of ferroptosis inhibitors, and application of the compounds and pharmaceutically acceptable salts thereof in preparation of drugs for treating and / or preventing neurodegenerative diseases, tissue ischemia reperfusion injury, cerebral apoplexy, cardiovascular diseases, renal failure, liver injury, diabetic complications, diabetes mellitus and the like. The invention relates to application in medicines for treating pancreatic cancer. # imgabs0 #

The present invention relates to a C-17 carbonyl-substituted oleanane triterpene derivative, a preparation method therefor, and a use thereof. Provided are a C-17 carbonyl-substituted oleanane triterpene derivative, a use of the compound in the preparation of an NRF2 activator, and preparation of a medicament for treating / preventing diseases. The diseases comprise cerebral small vascular disease, mitochondrial encephalomyopathy, autism spectrum disorder, Rett syndrome, Friedreich ataxia, stroke, hemorrhagic cerebral apoplexy, ischemic cerebral apoplexy, multiple sclerosis, amyotrophic lateral sclerosis, schizophrenia, schizophrenic cognitive impairment, Parkinson's disease, cognitive impairment in Parkinson's disease, Alzheimer's disease, vascular dementia, epilepsy, Huntington's disease, heart failure, myocardial infarction, renal failure, kidney ischemia, etc., or other disease states and conditions which are obvious to a person skilled in the art. Also provided are a prodrug thereof, or a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof, and a pharmaceutical composition containing same.

An extracorporeal and drug delivery system includes a renal failure therapy machine operable with a blood filter in fluid communication with an arterial line and a venous line, the machine including an effluent pump for pumping effluent from the blood filter, and at least one of a dialysis fluid pump for pumping dialysis fluid to the blood filter at a dialysis fluid flowrate, a predilution pump for pumping replacement fluid into the arterial line at a predilution flowrate, or a postdilution pump for pumping replacement fluid into the venous line at a postdilution flowrate; an infusion pump operable to deliver an intravenous (“IV”) drug to the patient; and a coordinating logic implementor configured to determine if a formulation adjustment should be made to the IV drug when a constituent of the IV drug exists in the dialysis fluid, the predilution replacement fluid, and / or the postdilution replacement fluid.

The present invention relates to a composition for preventing, ameliorating or treating diseases caused by nitration of tyrosine in a protein, comprising tyrosine as an active ingredient. The tyrosine as an active ingredient of the present invention not only enhances reduced GS activity, but also can restore the content (proportion) of glutamine and glutamic acid in the brain and the amount of ammonia to a normal state. The composition has an insulin sensitivity enhancing effect in a type 2 diabetes mellitus model, an excitatory toxicity and oxidative stress inhibiting effect in an epileptic seizure model, a cerebral infarction reducing and GS activity enhancing effect in a stroke model, a tyrosine denitration effect using human recombinant MnSOD, an acute renal failure effect, and a hyperammonemia effect. Therefore, the compound can be effectively used as a health-care functional food composition for preventing or alleviating diseases caused by tyrosine nitrification in proteins or as a pharmaceutical composition for preventing or treating diseases caused by tyrosine nitrification in proteins.